Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Conditions:   Fallopian Tube Carcinosarcoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Germline BRCA1 Gene Mutation;   Germline BRCA2 Gene Mutation;   High Grade Fallopian Tube Serous A denocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Tumor;   Ovarian Seromucinous Carcinoma;   Ovarian Undifferentiated Carcinoma;   Platinum-Sensitive Fallopian Tube Carcinoma;   Platinum-Sensitive Ovarian Carcinoma;   Platinum-Sensitive Primary  Peritoneal Carcinoma;   Primary Peritoneal Carcinosarcoma;   Primary Peritoneal Clear Cell Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Primary Peritoneal Transitional Cell Carcinoma;   Primary Peritoneal Undifferentiated Carcinoma;   Recurrent Fallopian  Tube Carcinoma;   Recurrent Ovarian Endometrioid Adenocarcinoma;   Recurrent Ovarian Serous Adenocarcinoma;   Recurrent Ovarian Transitional Cell Carcinoma;   Recurrent Primary Peritoneal Carcinoma Interventions:   Drug: Olaparib;   Biological: Tremelimumab Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials